New drug may spare hodgkin patients from harsh chemo before transplant
NCT ID NCT01508312
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant in 66 people with relapsed or refractory Hodgkin lymphoma. The drug targets cancer cells and has fewer side effects than ICE. Patients whose PET scans showed no active disease after two cycles went straight to transplant, while others received additional ICE. The goal was to see if some patients could safely avoid the more toxic chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin (SGN-35)
- What this could lead to
- If successful, this could offer a less toxic way to prepare Hodgkin lymphoma patients for stem cell transplant, potentially avoiding harsh chemotherapy for some.
- What could go wrong
- This is a small, early-phase study (66 people) without a comparison group. The drug may not work for everyone, and some patients still need additional chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial